Cargando…
Growth hormone therapy for Prader–willi syndrome: challenges and solutions
Prader–Willi syndrome (PWS) is characterized by a dysregulation of growth hormone (GH)/insulin-like growth factor I axis, as the consequence of a complex hypothalamic involvement. PWS’ clinical picture seems to resemble the classic non-PWS GH deficiency (GHD), including short stature, excessive body...
Autores principales: | Grugni, Graziano, Sartorio, Alessandro, Crinò, Antonino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898426/ https://www.ncbi.nlm.nih.gov/pubmed/27330297 http://dx.doi.org/10.2147/TCRM.S70068 |
Ejemplares similares
-
Long-term effects of GH therapy in adult patients with Prader-Willi syndrome: a longitudinal study
por: Grugni, Graziano, et al.
Publicado: (2023) -
Obesity management in Prader–Willi syndrome: current perspectives
por: Crinò, Antonino, et al.
Publicado: (2018) -
High Prevalence of Scoliosis in a Large Cohort of Patients with Prader-Willi Syndrome
por: Crinò, Antonino, et al.
Publicado: (2022) -
Hyperprolactinemia in Adults with Prader-Willi Syndrome
por: Sjöström, Anna, et al.
Publicado: (2021) -
Parameters of Glucose Homeostasis in the Recognition of the Metabolic Syndrome in Young Adults with Prader–Willi Syndrome
por: Grugni, Graziano, et al.
Publicado: (2021)